Chronic Effects of Ziprasidone, Aripiprazole, Blonanserin, Cyamemazine, and Nemonapride on Mice Isolated Detrusor Smooth Muscle

Abstract

Objective: Ziprasidone, aripiprazole, blonanserin, cyamemazine, and nemonapride are atypical antipsychotic drugs used for the treatment of schizophrenia. This study aimed to identify the effects of these atypical antipsychotic drugs in mice isolated bladder using the organ bath system

Materials and Methods: The mice were injected intraperitoneally with drugs for 21 days. The effects of drugs were investigated on isoproterenol-induced relaxation responses of carbachol-induced contractions in isolated detrusor strips. The detrusor strips were stimulated with KCl, then tissues were washed for a further 30 min and precontracted with a submaximal concentration of carbachol. After the contraction reached a plateau, cumulative concentration-response curves to isoproterenol were obtained.

Results: We showed that carbachol-induced contractions dose-dependently relaxed by isoproterenol in mice detrusor strips obtained from ziprasidone, aripiprazole, blonanserin, and cyamemazine but not nemonapride treated group. However, none of the drug treatments had any effect KCl responses of mice's bladder.

Conclusion: Ziprasidone, aripiprazole, blonanserin, and cyamemazine but not nemonapride increased the isoproterenol-induced relaxations of the detrusor smooth muscle indicates that it can increase the bladder capacity. We demonstrate that four drugs may represent a potential treatment for overactive bladder. They might be clinically useful for the treatment of overactive bladder in patients that should use antipsychotics. 

Keywords

• Aripiprazole
• blonanserin
• cyamemazine
• nemonapride
• ziprasidone

Ziprasidon, Aripiprazol, Blonanserin, Siyamemazin ve Nemonaprid'in Farelerde İzole Detrusor Düz Kasına Kronik Etkileri

Öz

Amaç: Ziprasidon, aripiprazol, blonanserin, siyamemazin ve nemonaprid şizofreni tedavisinde kullanılan atipik antipsikotik ilaçlardır. Bu çalışmada bu atipik antipsikotik ilaçların organ banyosu kullanılarak farelerde izole edilmiş mesane üzerine etkilerinin belirlenmesi amaçlanmıştır.

Materyal ve Metot: Fareler 21 gün boyunca intraperitoneal ilaç enjeksiyonu uygulandı. İlaçların izole detrusor şeritlerinde karbakolden kaynaklanan kasılmaların izoproterenol kaynaklı gevşeme tepkileri üzerindeki etkileri araştırıldı. Detrüsör şeritleri KCl ile uyarıldı, daha sonra dokular 30 dakika yıkandı ve submaksimal bir karbakol konsantrasyonu ile önceden kastırıldı. Kasılma belli bir platoya ulaştıktan sonra, izoproterenole kümülatif konsantrasyon-yanıt eğrileri elde edildi.

Bulgular: Karbakol kaynaklı kasılmaların ziprasidon, aripiprazol, blonanserin ve siyamemazin ile muamele edilen gruptan elde edilen fare detrusor şeritlerinde izoproterenol ile doza bağlı olarak gevşediğini gösterdik. Bununla birlikte, ilaç tedavilerinin hiçbiri, fare mesanelerinin KCl yanıtlarını etkilememiştir.

Sonuç: Nemonaprid dışında ziprasidon, aripiprazol, blonanserin ve siyamemazin, izoproterenol ile indüklenen detrüsör düz kas gevşemesi görülmesi mesane kapasitesini arttırabileceğini göstermektedir. Dört ilacın aşırı aktif mesane için potansiyel bir tedavi olabileceğini ön görmekteyiz. Bu ilaçlar, antipsikotikleri kullanması gereken hastalarda aşırı aktif mesane tedavisinde klinik olarak yararlı olabilir.  

Anahtar Kelimeler

• Aripiprazol
• blonanserin
• nemonaprid
• siyamemazin
• ziprasidon

Kaynakça

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2003;61(1):37-49. doi:10.1016/s0090-4295(02)02243-4
2. Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622-624. doi:10.1002/nau.22609
3. Chuang YC, Liu SP, Lee KS, et al. Prevalence of overactive bladder in China, Taiwanand South Korea: Results from a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019;11(1): 48-55.
4. Sadananda P, Drake MJ, Paton JF, Pickering AE. A functional analysis of the influence of β 3-adrenoceptors on the rat micturition cycle. J Pharmacol Exp Ther. 2013;347(2):506-515. doi:10.1124/jpet.113.207340
5. Daly D, Chapple C. Relationship between overactive bladder (OAB) and irritable bowel syndrome (IBS): concurrent disorders with a common pathophysiology? BJU Int. 2013;111(4):530-531. doi:10.1111/j.1464-410X.2013.11019.x
6. Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Compr Physiol. 2015;5(1): 327-396. doi:10.1002/cphy.c130056
7. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201. doi:10.1016/s0014-2999(01)01188-8
8. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411.

9. Bayazıt H, Kiliçaslan F. Diuarnal Enurisis Secondary to Aripiprazol. Mustafa Kemal Üniv Tıp Derg. 2017;8(31):36-38. doi:10.17944/mkutfd.376533
10. Kato K, Yamada K, Maehara M, et al. Blonanserin in the treatment of delirium. Psychiatry Clin. Neurosci. 2011;65:389-391. doi:10.1038/sj.npp.1300203
11. Min A, Kim D. Blonanserin-induced mood alteration in schizophrenia and schizoaffective disorder: two cases. Clin Psychopharmacol Neurosci. 2013;11(3):165-167. doi:10.9758/cpn.2013.11.3.165
12. Tata 1mg. https://www.1mg.com/generics/blonanserin-212560. Accessed March 3, 2003.
13. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18:63-101. doi:10.1016/S0893-133X(97)00112-7
14. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet. 1990;335(8698):1114-1117.
15. Tanyeri MH, Buyukokuroglu ME, Tanyeri P, et al. Effects of long-term treatment with haloperidol, clozapine and aripiprazole on mice isolated vas deferens. Int Urol Nephrol. 2017;49(9):1561-1567.
16. Bourin M, Nic Dhonnchadha BA, Claude Colombel M, Dib M, Hascoët M. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res. 2001;124(1):87-95.
17. Horiguchi M, Meltzer HY. Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism. Behav Brain Res. 2013;247:158-164. doi: 10.1016/j.bbr.2013.03.027
18. Auclair AL, Kleven MS, Besnard J, Depoortère R, Newman-Tancredi A. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology. 2006;31(9):1900-1909.
19. Patra P, Patra S. Research findings on overactive bladder. Curr Urol. 2015;8(1):1-21. doi:10.1159/000365682
20. Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. Rev Urol. 2003;(5):3-10.
21. Fowler CJ, Griffiths D, Groat WC. The neural control of micturition. Nature Reviews Neuroscience. 2008;9(6):453-466. doi:10.1038/nrn2401
22. Pineda RH, Nedumaran B, Hypolite J, et al. Altered expression and modulation of the two-pore-domain (K2P) mechanogated potassium channel TREK-1 in overactive human detrusor. Am J Physiol Renal Physiol. 2017;313:535–546. doi:10.1152/ajprenal.00638.2016
23. Groat WC, Wickens C. Organization of the neural switching circuitry underlying reflex micturition. Acta Physiologica. 2013;207(1):66-84. doi:10.1111/apha.12014
24. Zhang J, Cao M, Chen Y, et al. Increased expression of TREK-1 K+ channel in the dorsal root ganglion of rats with detrusor overactivity after partial bladder outlet obstruction. Med Sci Monit. 2018;24:1064-1071. doi:10.12659/MSM.908792
25. Lei Q, Pan XQ, Chang S, Malkowicz SB, Guzzo TJ, Malykhina AP. Response of the human detrusor to stretch is regulated by TREK-1, a two-pore-domain (K2P) mechano-gated potassium channel. J Physiol. 2014;592(14):3013-3030. doi:10.1113/jphysiol.2014.271718
26. Cadaveira-Mosquera A, Ribeiro SJ, Reboreda A, Lamas JA. Activation of TREK currents by the neuroprotective agent riluzole in mouse sympathetic neurons. J Neurosci.2011;31(4):1375-1385. doi:10.1523/JNEUROSCI.2791-10.2011
27. Picardo HP, Joseph H, Sanghee L, et al. Altered detrusor contractility and voiding patterns in mice lacking the mechanosensitive TREK-1 channel. BMC Urol. 2019;19:40. doi:10.1186/s12894-019-0475-3
28. Yoshimura N, Kuno S, Chancellor MB, De Groat WC, Seki S. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol. 2003;139(8):1425-1432. doi:10.1038/sj.bjp.0705388